Targeting PVR (CD155) and its receptors in anti-tumor therapy

• Published in: Cellular & molecular immunology Vol. 16; no. 1; pp. 40 - 52
• Main Authors: Kučan Brlić, Paola, Lenac Roviš, Tihana, Cinamon, Guy, Tsukerman, Pini, Mandelboim, Ofer, Jonjić, Stipan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2019; Nature Publishing Group
• Subjects: Animals; Antibodies; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer therapies; CD155 antigen; Cell cycle; Cell growth; Clinical Trials as Topic; Growth factors; Humans; Immunoglobulins; Immunology; Immunoregulation; Immunosuppression; Immunotherapy; Immunotherapy, Adoptive; Ligands; Medical Microbiology; Medical prognosis; Microbiology; Motility; Neoplasms - therapy; Oncolysis; Protein Binding; Proteins; Receptors, Immunologic - metabolism; Receptors, Virus - chemistry; Receptors, Virus - metabolism; Review; Review Article; Signal transduction; Therapeutic applications; Tumor markers; Vaccine; checkpoint; TIGIT; PVR; tumor; immunotherapy; poliovirus
• ISSN: 1672-7681; 2042-0226
• DOI: 10.1038/s41423-018-0168-y

Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.